[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 833
1. Tangen JM, Fløisand Y, Haukås E, Naess IA, Skjelbakken T, Stapnes C, Tjønnfjord GE: [Survival in adults with acute lymphoblastic leukaemia]. Tidsskr Nor Laegeforen; 2010 Sep 9;130(17):1710-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival in adults with acute lymphoblastic leukaemia].
  • BACKGROUND: The Norwegian treatment protocol for acute lymphoblastic leukaemia in adults was introduced in 1982 and has undergone minor changes thereafter.
  • This article presents survival data for Norwegian adults with acute lymphoblastic leukaemia on a national basis.
  • MATERIAL AND METHODS: Data for all patients between 15 and 65 years, who were diagnosed with acute lymphoblastic leukaemia in the period 2000-2007 according to The Norwegian Registry for Acute Leukaemia and Lymphoblastic Lymphoma, and were treated with chemotherapy with a curative intent were analysed for survival.
  • RESULTS: 128 patients were diagnosed with acute lymphoblastic leukaemia in the study period.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Middle Aged. Norway / epidemiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / mortality. Prognosis. Registries. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20835280.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


2. Molkenboer JF, Vos AH, Schouten HC, Vos MC: Acute lymphoblastic leukaemia in pregnancy. Neth J Med; 2005 Oct;63(9):361-3
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia in pregnancy.
  • Two cases of pregnant patients with acute lymphoblastic leukaemia (ALL) are presented.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma. Pregnancy Complications, Neoplastic

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244384.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


3. Inaba H, Pui CH: Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol; 2010 Nov;11(11):1096-106
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid use in acute lymphoblastic leukaemia.
  • Glucocorticoids (prednisone and dexamethasone) play an essential part in the treatment of acute lymphoblastic leukaemia (ALL), but their optimum doses and bioequivalence have not been established.
  • In prospective randomised trials, dexamethasone improved control of CNS leukaemia.
  • At a prednisone-to-dexamethasone dose ratio of less than seven, dexamethasone (6-18 mg/m(2) per day) resulted in a better event-free survival than did prednisone (40-120 mg/m(2) per day), and high-dose dexamethasone (10-18 mg/m(2) per day) improved the outcome of T-cell ALL and high-risk ALL.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Blood. 2009 Feb 26;113(9):2014-21 [18978206.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Blood. 2009 Aug 27;114(9):1746-52 [19546477.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):957-66 [19747876.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1018-25 [19965632.001]
  • [Cites] Clin Exp Neurol. 1984;20:107-18 [6568935.001]
  • [Cites] Endocrinol Jpn. 1984 Oct;31(5):583-94 [6519032.001]
  • [Cites] Cancer Res. 1985 Dec;45(12 Pt 1):6482-6 [3864532.001]
  • [Cites] J Pharm Sci. 1986 Oct;75(10):973-5 [3795028.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):202-7 [3806166.001]
  • [Cites] Cell. 1988 Oct 21;55(2):361-9 [3167984.001]
  • [Cites] Ann Allergy. 1991 May;66(5):414-9 [2035905.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):269-75 [2056971.001]
  • [Cites] Neurology. 1991 Aug;41(8):1235-9 [1866012.001]
  • [Cites] Blood. 1992 May 1;79(9):2370-7 [1373973.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):752-6 [8290595.001]
  • [Cites] Endocr Rev. 1993 Dec;14(6):659-69 [8119231.001]
  • [Cites] J Neurosci. 1994 Apr;14(4):2047-53 [8198631.001]
  • [Cites] Psychoneuroendocrinology. 1994;19(3):233-55 [7515507.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):911-8 [8622039.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):114-21 [8649318.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2370-6 [8708730.001]
  • [Cites] Leukemia. 1998 Apr;12(4):619-22 [9557622.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1964-9 [10760775.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):206-13 [10864051.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3262-72 [10986059.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1040-6 [11181667.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3066-72 [11408503.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3742-5 [11502805.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2898-903 [12767105.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Clin Invest. 1973 Jul;52(7):1715-25 [4352461.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Jun;40(6):1073-7 [1133157.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Aug;41(2):290-304 [169279.001]
  • [Cites] Am J Med. 1977 Aug;63(2):200-7 [888843.001]
  • [Cites] Am Fam Physician. 1978 Mar;17(3):198-204 [629197.001]
  • [Cites] J Pediatr. 1978 Aug;93(2):299-303 [671172.001]
  • [Cites] J Cell Physiol. 1979 Feb;98(2):267-78 [422656.001]
  • [Cites] Nature. 1980 Apr 10;284(5756):555-6 [6245367.001]
  • [Cites] Cancer Res. 1981 Oct;41(10):3979-84 [7285007.001]
  • [Cites] J Immunol. 1984 Jul;133(1):273-6 [6427338.001]
  • [Cites] N Engl J Med. 1998 Jul 30;339(5):292-9 [9682041.001]
  • [Cites] J Am Med Assoc. 1950 Dec 16;144(16):1349-53 [14778746.001]
  • [Cites] Pediatr Blood Cancer. 2005 Mar;44(3):220-5 [15514916.001]
  • [Cites] Pharmacol Rep. 2005 Jan-Feb;57(1):47-54 [15849376.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6489-98 [16170158.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1279-87 [16688224.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1045-9 [16574952.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Lancet. 2007 Jan 13;369(9556):123-31 [17223475.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1525-31 [17442995.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Arthritis Res Ther. 2007;9 Suppl 1:S7 [17634146.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(17):2532-6 [17702568.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):257-68 [18308251.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1932-9 [18421047.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3038-45 [18565890.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):376-82 [18459178.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):85-7 [19185842.001]
  • (PMID = 20947430.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-34; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids
  • [Other-IDs] NLM/ NIHMS319128; NLM/ PMC3309707
  •  go-up   go-down


Advertisement
4. Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet; 2008 Mar 22;371(9617):1030-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects both children and adults, with peak prevalence between the ages of 2 and 5 years.
  • Steady progress in development of effective treatments has led to a cure rate of more than 80% in children, creating opportunities for innovative approaches that would preserve past gains in leukaemia-free survival while reducing the toxic side-effects of current intensive regimens.
  • Advances in our understanding of the pathobiology of acute lymphoblastic leukaemia, fuelled by emerging molecular technologies, suggest that drugs specifically targeting the genetic defects of leukaemic cells could revolutionise management of this disease.
  • Meanwhile, studies are underway to ascertain the precise events that take place in the genesis of acute lymphoblastic leukaemia, to enhance the clinical application of known risk factors and antileukaemic agents, and to identify treatment regimens that might boost the generally low cure rates in adults and subgroups of children with high-risk leukaemia.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358930.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA68484; United States / NINR NIH HHS / NR / NR07610; United States / NCI NIH HHS / CA / CA36401; United States / NCI NIH HHS / CA / CA90246; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA78224; United States / NCI NIH HHS / CA / CA52259; United States / NCI NIH HHS / CA / CA60419; United States / NIGMS NIH HHS / GM / GM61393; United States / NCI NIH HHS / CA / CA06516; United States / NCI NIH HHS / CA / CA51001; United States / NCI NIH HHS / CA / P30 CA006516
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 171
  •  go-up   go-down


5. Payne JH, Vora AJ: Thrombosis and acute lymphoblastic leukaemia. Br J Haematol; 2007 Aug;138(4):430-45
MedlinePlus Health Information. consumer health - Blood Clots.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombosis and acute lymphoblastic leukaemia.
  • Venous thrombosis is more frequent in patients treated for acute lymphoblastic leukaemia (ALL) than other malignancies and has distinctive causes, clinical features and remedies.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Thrombosis / complications

  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608766.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 103
  •  go-up   go-down


6. Burkhardt B: Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases? Br J Haematol; 2010 Jun;149(5):653-68
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases?
  • There is ongoing discussion on whether paediatric acute T-cell lymphoblastic leukaemia (T-ALL) and paediatric lymphoblastic T-cell lymphoma (T-LBL) are two distinct entities or whether they represent two variant manifestations of one and the same disease and the distinction is arbitrary.
  • The current World Health Organization classification designates both malignancies as T lymphoblastic leukaemia/lymphoma.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961482.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


7. Yasmeen N, Ashraf S: Childhood acute lymphoblastic leukaemia; epidemiology and clinicopathological features. J Pak Med Assoc; 2009 Mar;59(3):150-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute lymphoblastic leukaemia; epidemiology and clinicopathological features.
  • OBJECTIVE: To study epidemiology, clinical presentation and laboratory features of childhood Acute Lymphoblastic Leukaemia.
  • METHOD: This retrospective review included all newly diagnosed children with acute lymphoblastic Leukaemia less than 15 years of age registered from April 1999 to December 2004 at oncology unit of National Institute of Child Health and Children Cancer Hospital, Karachi.
  • RESULTS: Acute lymphoblastic Leukaemia constituted 32% (611 /1890) of all cancers in this study.
  • Initial high white cell count (> 50,000) was observed in 34% patients.
  • CONCLUSION: Acute Lymphoblastic Leukaemia accounts for one third of total registered cases.
  • The fraction with a WBC count above 50,000 mm3 (30%), a higher proportion with lymphadenopathy (75%) and haemoglobin less than 7 gm/dl (54%) suggest that Pakistani children have significantly higher burdens of Leukaemia cells at presentation.
  • These may have prognostic implication resulting in poor outcome of Leukaemia in this part of the world.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288940.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


8. Stankovic T, Marston E: Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia. Srp Arh Celok Lek; 2008 Mar-Apr;136(3-4):187-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia (ALL) is the most common paediatric cancer.
  • These microarray studies have shown that genes discriminating between clinically responsive and resistant leukaemias tend to be involved in cellular processes such as regulation of cell cycle, proliferation, and DNA repair.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18720757.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Serbia
  • [Number-of-references] 60
  •  go-up   go-down


9. Cobaleda C, Sánchez-García I: B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays; 2009 Jun;31(6):600-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin.
  • B-cell acute lymphoblastic leukaemia (B-ALL) is a clonal malignant disease originated in a single cell and characterized by the accumulation of blast cells that are phenotypically reminiscent of normal stages of B-cell differentiation.
  • B-ALL origin has been a subject of continuing discussion, given the fact that human disease is diagnosed at late stages and cannot be monitored during its natural evolution from its cell of origin, although most B-ALLs probably start off with chromosomal changes in haematopoietic stem cells.
  • The results from these different reconstitution experiments and their interpretations are compared in this review in the context of normal B-cell developmental plasticity.
  • [MeSH-major] B-Lymphocytes / physiology. Leukemia, B-Cell / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cell Differentiation / physiology. Humans. Neoplastic Stem Cells / cytology. Neoplastic Stem Cells / physiology. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444834.001).
  • [ISSN] 1521-1878
  • [Journal-full-title] BioEssays : news and reviews in molecular, cellular and developmental biology
  • [ISO-abbreviation] Bioessays
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 63
  •  go-up   go-down


10. Sweetenham JW: Highly aggressive lymphomas in adults. Hematol Oncol Clin North Am; 2008 Oct;22(5):965-78, ix
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The designation of "highly aggressive" is generally restricted to precursor T-cell and B-cell lymphoblastic lymphoma/leukemia and Burkitt's lymphoma/leukemia.
  • Treatment strategies for lymphoblastic lymphoma and Burkitt's lymphoma include complex, highly intensive combination chemotherapy regimens, which may be curative.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18954746.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


11. Ali R, Brooke A, Luker J: Acute lymphoblastic leukaemia: an unusual radiological presentation. Dentomaxillofac Radiol; 2009 Jul;38(5):289-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia: an unusual radiological presentation.
  • A 14-year-old female patient attended Bristol Dental Hospital for an oral screening prior to undergoing a bone marrow transplant as treatment for her acute lymphoblastic leukaemia.
  • These radiological features (coupled with the patient's age) would have correlated with a diagnosis of Langerhans cell histiocytosis.
  • However, a previous bone marrow biopsy confirmed that the patient did indeed have acute lymphoblastic leukaemia.
  • We feel that this radiological presentation of leukaemia needs to be reported as these features could easily have been confused with other haematological or even malignant conditions.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiography
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Histiocytosis, Langerhans-Cell / radiography. Humans. Mandible / radiography. Skull / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474256.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Harrison CJ: Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol; 2009 Jan;144(2):147-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia.
  • Cytogenetics has determined the incidence and prognostic significance of chromosomal abnormalities in acute lymphoblastic leukaemia (ALL).
  • Five 'hot topics' are presented in which cytogenetics and related techniques have been instrumental in understanding the role of genetics in leukaemogenesis: (i) genetic changes are integral to the biology of T-cell ALL;.
  • (ii) intrachromosomal amplification of chromosome 21 is a new recurrent abnormality in precursor-B ALL (BCP-ALL);.
  • (iv) alterations in genes involved in B-cell development and cell cycle control contribute to the pathogenesis of BCP-ALL;.
  • [MeSH-major] Chromosome Aberrations. Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006567.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 74
  •  go-up   go-down


13. Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP: Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol; 2008 Oct;143(2):153-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia.
  • Paediatric T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive malignancy of thymocytes that accounts for about 15% of ALL cases and for which treatment outcome remains inferior compared to B-lineage acute leukaemias.
  • In T-ALL, leukemic transformation of maturating thymocytes is caused by a multistep pathogenesis involving numerous genetic abnormalities that drive normal T-cells into uncontrolled cell growth and clonal expansion.
  • Type A abnormalities may delineate distinct molecular-cytogenetic T-ALL subgroups, whereas type B abnormalities are found in all major T-ALL subgroups and synergize with these type A mutations during T-cell pathogenesis.
  • [MeSH-major] Genes, Homeobox. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogenes. Receptors, Antigen, T-Cell / genetics. Signal Transduction / genetics
  • [MeSH-minor] Cell Cycle / genetics. Cell Differentiation / genetics. Child. Gene Rearrangement, T-Lymphocyte. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691165.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 136
  •  go-up   go-down


14. Uyttebroeck A, Vanhentenrijk V, Hagemeijer A, Boeckx N, Renard M, Wlodarska I, Vandenberghe P, Depaepe P, De Wolf-Peeters C: Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma; 2007 Sep;48(9):1745-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?
  • To distinguish the similarities or differences between T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), we retrospectively analyzed the clinical, immunophenotypic, cytogenetic, and molecular characteristics in 37 children diagnosed between December 1990 and December 2003.
  • The differences that were found between both neoplasms, in particular in their phenotype and in their expression profile may suggest that most T-ALL derive from a T-cell progenitor of the bone marrow, while thymocytes represent the normal counterpart of T-LBL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786710.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Zainina S, Cheong SK: Myelodysplastic syndrome transformed into Acute Lymphoblastic Leukaemia (FAB:L3). Clin Lab Haematol; 2006 Aug;28(4):282-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndrome transformed into Acute Lymphoblastic Leukaemia (FAB:L3).
  • Myelodysplastic syndrome (MDS) is recognized as a preleukaemic disorder with a variable risk of transformation to acute myeloid leukaemia.
  • Usually the blast cells in leukaemia are transformed after MDS displays a myeloid phenotype.
  • We report a case of an elderly man who had MDS transformed into Acute Lymphoblastic Leukaemia (ALL:L3) which is a rare lymphoid transformation.
  • [MeSH-major] Anemia, Refractory / pathology. Burkitt Lymphoma / pathology. Cell Transformation, Neoplastic / pathology

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898972.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Commander LA, Seif AE, Insogna IG, Rheingold SR: Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol; 2010 Aug;150(3):345-51
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
  • A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Arabinonucleosides / administration & dosage. Arabinonucleosides / adverse effects. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hematologic Diseases / chemically induced. Hematopoietic Stem Cell Transplantation. Humans. Male. Nervous System Diseases / chemically induced. Recurrence. Remission Induction / methods. Salvage Therapy / adverse effects. Salvage Therapy / methods. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528871.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


17. Jones LK, Saha V: Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol; 2005 Aug;130(4):489-500
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia positive acute lymphoblastic leukaemia of childhood.
  • On current chemotherapeutic regimens, children with Philadelphia positive acute lymphoblastic leukaemia show a heterogeneous response to treatment.
  • Relapse on treatment is common and remission is sustained in a proportion of cases only after allogeneic stem cell transplantation (allo-SCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Child. Humans. Imatinib Mesylate. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Remission Induction / methods. Stem Cell Transplantation. Transplantation, Homologous

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098062.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 123
  •  go-up   go-down


18. Li S: Src kinases as targets for B cell acute lymphoblastic leukaemia therapy. Expert Opin Ther Targets; 2005 Apr;9(2):329-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Src kinases as targets for B cell acute lymphoblastic leukaemia therapy.
  • The participation of Src kinases in the induction of BCR-ABL-induced B cell acute lymphoblastic leukaemia (B-ALL), but not chronic myeloid leukaemia (CML), demonstrates cell type-specific signalling in Philadelphia chromosome-positive (Ph+) leukaemias.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / enzymology. Drug Delivery Systems / methods. Protein Kinase Inhibitors / therapeutic use. src-Family Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934919.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / src-Family Kinases
  • [Number-of-references] 114
  •  go-up   go-down


19. Thomas X: Emerging drugs for adult acute lymphoblastic leukaemia. Expert Opin Emerg Drugs; 2005 Aug;10(3):591-617
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for adult acute lymphoblastic leukaemia.
  • Although most patients with adult acute lymphoblastic leukaemia (ALL) can achieve a remission when treated with conventional, DNA-damaging chemotherapy, in more than half of all cases the disease relapses and ultimately results in death.
  • Here, the targeting of a molecular abnormality--inhibition of BCR-ABL tyrosine kinase--has turned a very poor-prognosis disease into one in which promising results are achieved.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Industry / trends. Drugs, Investigational / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083331.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  • [Number-of-references] 162
  •  go-up   go-down


20. Stam RW, den Boer ML, Pieters R: Towards targeted therapy for infant acute lymphoblastic leukaemia. Br J Haematol; 2006 Mar;132(5):539-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Towards targeted therapy for infant acute lymphoblastic leukaemia.
  • Despite the greatly improved treatment regimes for childhood acute lymphoblastic leukaemia (ALL) in general, resulting in long-term survival in approximately 80% of cases, current therapies still fail in >50% of ALL cases diagnosed within the first year of life (i.e. in infants).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Age of Onset. Forecasting. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Infant. Mutation. Myeloid-Lymphoid Leukemia Protein / genetics. Prognosis. Remission Induction. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445826.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 139
  •  go-up   go-down


21. Rowe JM: Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol; 2010 Aug;150(4):389-405
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in adult acute lymphoblastic leukaemia.
  • Treatment of acute lymphoblastic leukaemia (ALL) in adults presents a formidable challenge.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20573154.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 121
  •  go-up   go-down


22. Khan NI, Bradstock KF, Bendall LJ: Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol; 2007 Aug;138(3):338-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia.
  • This study investigated the response of acute lymphoblastic leukaemia (ALL) cells to Wnt proteins.
  • Reverse transcription polymerase chain reaction (RT-PCR) analysis of B-cell progenitor acute lymphoblastic leukaemia (ALL) cells revealed expression of Wnt genes, including WNT2B in 33%, WNT5A in 42%, WNT10B in 58% and WNT16B in 25% of cases.
  • This resulted in a 1.7- to 5.3-fold increase in cell proliferation, which was associated with enhanced cell cycle entry.
  • Microarray analysis and quantitative RT-PCR revealed that activation of the Wnt/beta-catenin pathway led to altered expression of genes involved in cell cycle regulation and apoptosis in normal and leukaemic B-cell progenitors.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Gene Expression Regulation, Leukemic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Signal Transduction / physiology. Wnt Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adolescent. Adult. Apoptosis / genetics. Blotting, Western / methods. Cell Cycle Proteins / genetics. Child. Child, Preschool. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured. Wnt3 Protein. Wnt3A Protein

  • Guide to Pharmacology. gene/protein/disease-specific - FZD4 - data and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614820.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / WNT3A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / beta Catenin
  •  go-up   go-down


23. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed. Prescrire Int; 2009 Feb;18(99):3-5
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
  • 1) Acute T-lymphoblastic leukaemia and T-lymphoblastic lymphoma are closely related malignant haemopathies.
  • However, only haematopoietic stem cell transplantation following chemotherapy offers a chance of long-term survival;.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382393.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Arabinonucleosides
  •  go-up   go-down


24. Gaynon PS: Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol; 2005 Dec;131(5):579-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute lymphoblastic leukaemia and relapse.
  • Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer.
  • We have salvage regimens with substantial complete remission (CR) rates and increasing access to haematopoietic stem cell transplantation, but most patients who relapse die.
  • [MeSH-major] Neoplasm, Residual / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Salvage Therapy / methods
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Hematopoietic Stem Cell Transplantation. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351633.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 90
  •  go-up   go-down


25. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ: Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol; 2008 Sep;9(9):873-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone-marrow relapse in paediatric acute lymphoblastic leukaemia.
  • Marrow relapse is the major obstacle to cure for 10-15% of young patients with acute lymphoblastic leukaemia (ALL).
  • Treatment of marrow relapse involves higher doses and more intensive schedules of the drugs used for initial therapy with or without haemopoietic stem cell transplantation.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Bone Marrow / pathology. Child. Combined Modality Therapy. Hematopoietic Stem Cell Transplantation / methods. Humans. Neoplasm, Residual / pathology. Risk Assessment. Secondary Prevention. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760243.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 85
  •  go-up   go-down


26. Whitlock JA: Down syndrome and acute lymphoblastic leukaemia. Br J Haematol; 2006 Dec;135(5):595-602
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down syndrome and acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia in children with Down syndrome (ALL-DS) is characterised by unique clinical and biological features.
  • [MeSH-major] Down Syndrome / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054672.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 U10 CA098543-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 77
  •  go-up   go-down


27. Kars MC, Duijnstee MS, Pool A, van Delden JJ, Grypdonck MH: Being there: parenting the child with acute lymphoblastic leukaemia. J Clin Nurs; 2008 Jun;17(12):1553-62
MedlinePlus Health Information. consumer health - Parenting.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Being there: parenting the child with acute lymphoblastic leukaemia.
  • AIMS AND OBJECTIVES: To gain insight into the lived experience of parenting a child with leukaemia during treatment.
  • BACKGROUND: Diagnosis of leukaemia in children leads to an existential shock for parents and a reversal of normal family life.
  • RELEVANCE TO CLINICAL PRACTICE: The concept offers an essential insight into parenting the child with acute lymphoblastic leukaemia and has relevance for nursing practice and education.
  • [MeSH-major] Attitude to Health. Parent-Child Relations. Parenting / psychology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482117.001).
  • [ISSN] 1365-2702
  • [Journal-full-title] Journal of clinical nursing
  • [ISO-abbreviation] J Clin Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Sikorska-Fic B, Stańczak E, Matysiak M, Kamiński A: [Acute pancreatitis during chemotherapy of acute lymphoblastic leukaemia complicated with pseudocyst]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1051-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute pancreatitis during chemotherapy of acute lymphoblastic leukaemia complicated with pseudocyst].
  • They were diagnosed to have acute lymphoblastic leukaemia and were treated according to the ALLLIC BFM 2002 protocol.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Pancreatic Pseudocyst / complications. Pancreatitis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531825.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


29. Corthals SL, Wynne K, She K, Shimizu H, Curman D, Garbutt K, Reid GS: Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Br J Haematol; 2006 Feb;132(4):452-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and, although current therapy is widely effective, relapse remains a significant clinical problem for which new treatment strategies are required.
  • The ligation of Toll-like receptors (TLR) on antigen-presenting cells stimulates the generation of strong T-cell helper type 1 (Th1) adaptive immune responses.
  • Although TLR9 ligation has been shown to enhance immunogenicity of a number of leukaemia cell types, there have been few reports of the effects mediated through other TLR.
  • In this study we analysed both the expression of TLR by B-cell precursor ALL cell lines and the effects of individual TLR ligation on the ability of ALL cells to stimulate allogeneic T cells.
  • While ligation of TLR2, TLR 7 and TLR9 led to detectable changes in ALL costimulatory molecule expression, only TLR2 and TLR9 stimulation influenced T-cell responses.
  • The TLR2 ligand Pam3CysSerLys4 provoked the most significant changes in T-cell response, dramatically augmenting interferon-gamma production.
  • [MeSH-major] Immunotherapy / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Toll-Like Receptors / metabolism
  • [MeSH-minor] Antigens, CD40 / metabolism. Cell Line, Tumor. Cell Proliferation. Guanosine / analogs & derivatives. Guanosine / pharmacology. Humans. Interferon-gamma / immunology. Ligands. Peptidoglycan / pharmacology. Protein Binding. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Stimulation, Chemical. T-Lymphocytes, Helper-Inducer / immunology. Toll-Like Receptor 1 / metabolism. Toll-Like Receptor 2 / metabolism. Toll-Like Receptor 3 / metabolism. Toll-Like Receptor 4 / metabolism. Toll-Like Receptor 5 / metabolism. Toll-Like Receptor 7 / metabolism. Toll-Like Receptor 9 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412017.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Ligands; 0 / Peptidoglycan; 0 / RNA, Messenger; 0 / Toll-Like Receptor 1; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 3; 0 / Toll-Like Receptor 4; 0 / Toll-Like Receptor 5; 0 / Toll-Like Receptor 7; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors; 12133JR80S / Guanosine; 82115-62-6 / Interferon-gamma; 9CAS0V66OI / loxoribine
  •  go-up   go-down


30. Aifantis I, Raetz E, Buonamici S: Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol; 2008 May;8(5):380-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of T-cell leukaemia and lymphoma.
  • T-cell acute lymphoblastic leukaemia (T-ALL) is induced by the transformation of T-cell progenitors and mainly occurs in children and adolescents.
  • We also compare the physiological progression of T-cell differentiation with T-cell transformation, highlighting the close relationship between these two processes.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18421304.001).
  • [ISSN] 1474-1741
  • [Journal-full-title] Nature reviews. Immunology
  • [ISO-abbreviation] Nat. Rev. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA105129; United States / NCI NIH HHS / CA / R01CA105129; United States / NCI NIH HHS / CA / T32 CA-09161
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / NF-kappa B; 0 / Receptor, Notch1; 0 / Transcription Factors; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Number-of-references] 101
  •  go-up   go-down


31. Hur M, Park JY, Cho HC, Lee KM, Shin HY, Cho HI: Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin Lab Haematol; 2006 Jun;28(3):154-9
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population.
  • They were acute lymphoblastic leukaemia (ALL, n = 89), acute myeloid leukaemia (AML, n = 55), biphenotypic acute leukaemia (n = 12), chronic myelogenous leukaemia (CML, n = 40), and normal controls (n = 200).
  • [MeSH-major] Folic Acid / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Acute / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706930.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


32. Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, Suzuki N, Hara J, Horibe K, Hayashi Y: FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol; 2009 Apr;145(2):198-206
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma.
  • Mutation analysis of FBXW7 and NOTCH1 genes was performed in 55 T cell acute lymphoblastic leukaemia (T-ALL) and 14 T cell non-Hodgkin lymphoma (T-NHL) patients who were treated on the Japan Association of Childhood Leukaemia Study (JACLS) protocols ALL-97 and NHL-98.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Gene Expression Regulation, Leukemic. Lymphoma, T-Cell / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics


33. Cox DP, Treseler P, Dong R, Jordan RC: Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun;103(6):814-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature.
  • Lymphoblastic lymphoma is an uncommon malignancy, with most cases showing a T-cell phenotype and presenting as a mediastinal mass.
  • By contrast, B-cell lymphoblastic lymphoma/leukemia is a rare high-grade malignancy that comprises approximately 10% of all lymphoblastic lymphomas.
  • Lymphomas of the oral cavity are rare and typically present as intraosseous lesions that are most commonly diffuse large B-cell type.
  • Here we present what we believe is the first B-cell lymphoblastic lymphoma initially presenting in the oral cavity.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Mandibular Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antigens, CD / analysis. Antigens, CD20 / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / analysis. Cyclophosphamide / administration & dosage. DNA Nucleotidylexotransferase / analysis. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Immunophenotyping. Middle Aged. Prednisone / administration & dosage. Proto-Oncogene Proteins c-bcl-2 / analysis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531941.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Proto-Oncogene Proteins c-bcl-2; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.7.31 / DNA Nucleotidylexotransferase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 37
  •  go-up   go-down


34. Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE: [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]. Tidsskr Nor Laegeforen; 2008 Nov 20;128(22):2563-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia].
  • BACKGROUND: The success rate for chemotherapy of adults with acute lymphoblastic leukaemia in Norway compares favourably with that in international reports, but improvements are still needed.
  • Allogeneic stem cell transplantation is an option for patients up to 60 years and may contribute to improving the outcome for these patients.
  • MATERIAL AND METHODS: Allogen stem cell transplantation was performed in 61 high-risk patients (38 men and 23 women) with acute lymphoblastic leukaemia at Rikshospitalet between 1985 and 2005.
  • Estimated 5-year actuarial leukemia-free survival was 35 %.
  • INTERPRETATION: Our results are in line with international reports on the results of allogen stem cell transplantation in high-risk acute lymphoblastic leukaemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023351.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


35. Hedeland RL, Hvidt K, Nersting J, Rosthøj S, Dalhoff K, Lausen B, Schmiegelow K: DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother Pharmacol; 2010 Aug;66(3):485-91
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
  • PURPOSE: To explore the DNA incorporation of 6-thioguanine nucleotide levels (DNA-6TGN) during 6-mercaptopurine (6MP) therapy of childhood acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL) and its relation to erythrocyte levels of their metabolites: 6-thioguanine-nucleotides (E-6TGN), methylated metabolites (E-MeMP), Methotrexate polyglutamates (E-MTX), and to thiopurine methyltransferase activity (TPMT).
  • E-MeMP levels were correlated to the DNA-TGN index (r (p) = 0.60, p = 0.008), indicating that high levels of MeMP result in enhanced DNA-6TGN incorporation, possibly due to inhibition of purine de novo synthesis, mediated by some of the methylated 6MP metabolites.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Child. Child, Preschool. Cytosol / metabolism. Drug Monitoring. Female. Humans. Infant. Lymphoma, Non-Hodgkin / drug therapy. Male. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Purines / antagonists & inhibitors. Purines / biosynthesis


36. Meijerink JP: Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol; 2010 Sep;23(3):307-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia.
  • Mutually exclusive oncogenic rearrangements may delineate specific T-cell acute lymphoblastic leukaemia (T-ALL) subgroups, and so far at least 4 molecular-cytogenetic subgroups have been identified, i.e. the TAL/LMO, the TLX1/HOX11, the TLX3/HOX11L2 and the HOXA subgroups.
  • A fifth group with an immature immunophenotype that can be predicted by an early T-cell precursor signature has also been identified, and has been associated with poor outcome.
  • The association of these subgroups with the expression of specific immunophenotypic markers reflecting arrest at specific T-cell developmental stages will be reviewed.
  • [MeSH-major] Gene Rearrangement. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 21112032.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / NOTCH1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


37. Boag JM, Beesley AH, Firth MJ, Freitas JR, Ford J, Hoffmann K, Cummings AJ, de Klerk NH, Kees UR: Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia; 2006 Oct;20(10):1731-7
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia.
  • To date there has been no definitive research documenting metabolic changes in acute lymphoblastic leukaemia (ALL) cells.
  • (1) higher expression of the glucose transport protein glucose transporter 1 in ALL compared to CD34+ specimens, (2) the excessive production of lactate in ALL cell lines and (3) sensitivity of ALL cell lines to the glycolysis inhibitor 2-deoxy-D-glucose.
  • [MeSH-major] B-Lymphocytes / metabolism. Glucose / pharmacokinetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Antigens, CD34 / metabolism. Cell Line, Tumor. Child. Citric Acid Cycle / genetics. Deoxyglucose / pharmacokinetics. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Glucose Transporter Type 1 / genetics. Glucose Transporter Type 1 / metabolism. Glycolysis / genetics. Humans. Lactic Acid / metabolism. RNA, Messenger / metabolism. Up-Regulation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041637.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Glucose Transporter Type 1; 0 / RNA, Messenger; 33X04XA5AT / Lactic Acid; 9G2MP84A8W / Deoxyglucose; IY9XDZ35W2 / Glucose
  •  go-up   go-down


38. Naresh KN, May PC, Reid AG, Marks AJ, Macdonald D, Kanfer E: T cell lymphoblastic leukaemia/lymphoma associated with a microenvironment of thymic asteroid B cells in the bone marrow. Histopathology; 2010 Oct;57(4):549-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell lymphoblastic leukaemia/lymphoma associated with a microenvironment of thymic asteroid B cells in the bone marrow.
  • It is currently unclear whether these cells are identifiable in T cell lymphoblastic leukaemia/lymphoma (T-ALL/LBL) of the thymus.
  • Cytogenetic analysis in one showed a complex translocation involving the T cell receptor beta (TCRB) gene at 7q35 and a distal region of 9q known to harbour the NOTCH1 gene.
  • CONCLUSION:   This is the first report of T-ALL/LBL documenting the presence of an asteroid B cell-rich microenvironment at bone marrow and LN sites.
  • [MeSH-major] B-Lymphocytes / pathology. Bone Marrow / pathology. Lymph Nodes / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Thymus Gland / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20875071.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Rafferty AL, Collett MG, Forsyth SF, Neumann EJ, Suepaul RB: Acute B-cell lymphoblastic leukaemia in a 5-month-old boar. N Z Vet J; 2007 Oct;55(5):244-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute B-cell lymphoblastic leukaemia in a 5-month-old boar.
  • Cytology of peripheral blood and bone marrow identified large numbers of lymphoblasts, which were demonstrated using immunocytochemistry to be of B-cell origin.
  • Histological examination of multiple organs also showed lymphoblastic infiltration.
  • DIAGNOSIS: B-cell lymphoblastic leukaemia with secondary infiltration of lymphoid organs, kidneys, testis and preputial skin.
  • CLINICAL RELEVANCE: This is the fi rst known reported case of acute B-cell lymphoblastic leukaemia in swine.
  • [MeSH-major] Burkitt Lymphoma / veterinary. Swine Diseases / diagnosis
  • [MeSH-minor] Animals. Blood Cell Count / veterinary. Diagnosis, Differential. Lethargy / etiology. Lethargy / veterinary. Male. Swine

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928902.001).
  • [ISSN] 0048-0169
  • [Journal-full-title] New Zealand veterinary journal
  • [ISO-abbreviation] N Z Vet J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


40. Panetta JC, Evans WE, Cheok MH: Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells. Br J Cancer; 2006 Jan 16;94(1):93-100
Hazardous Substances Data Bank. MERCAPTOPURINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells.
  • The antimetabolite mercaptopurine (MP) is widely used to treat childhood acute lymphoblastic leukaemia (ALL).
  • To study the dynamics of MP on the cell cycle, we incubated human T-cell leukaemia cell lines (Molt-4 sensitive and resistant subline and P12 resistant) with 10 microM MP and measured total cell count, cell cycle distribution, percent viable, percent apoptotic, and percent dead cells serially over 72 h.
  • We developed a mathematical model of the cell cycle dynamics after treatment with MP and used it to show that the Molt-4 sensitive controls had a significantly higher rate of cells entering apoptosis (2.7-fold, P<0.00001) relative to the resistant cell lines.
  • Additionally, when treated with MP, the sensitive cell line showed a significant increase in the rate at which cells enter apoptosis compared to its controls (2.4-fold, P<0.00001).
  • Of note, the resistant cell lines had a higher rate of antimetabolite incorporation into the DNA of viable cells (>1.4-fold, P<0.01).
  • Lastly, in contrast to the other cell lines, the Molt-4 resistant subline continued to cycle, though at a rate slower relative to its control, rather than proceed to apoptosis.
  • This led to a larger S-phase block in the Molt-4 resistant cell line, but not a higher rate of cell death.
  • Gene expression of apoptosis, cell cycle, and repair genes were consistent with mechanistic dynamics described by the model.
  • In summary, the mathematical model provides a quantitative assessment to compare the cell cycle effects of MP in cells with varying degrees of MP resistance.
  • [MeSH-major] 6-Mercaptopurine / pharmacology. Antimetabolites, Antineoplastic / pharmacology. Cell Cycle / drug effects. Models, Theoretical. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Aug 1;104(3):822-8 [15090454.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 1;68(5):911-21 [15294454.001]
  • [Cites] Cancer Res. 1983 Aug;43(8):3852-6 [6861150.001]
  • [Cites] Mol Pharmacol. 1992 Nov;42(5):802-7 [1331762.001]
  • [Cites] Biochemistry. 1997 Mar 4;36(9):2501-6 [9054555.001]
  • [Cites] Blood. 1999 May 1;93(9):2817-23 [10216075.001]
  • [Cites] Mol Pharmacol. 1999 Oct;56(4):841-8 [10496969.001]
  • [Cites] FASEB J. 2000 Nov;14(14):2339-44 [11053256.001]
  • [Cites] Math Biosci. 2001 Mar;170(1):1-16 [11259801.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5810-6 [11479220.001]
  • [Cites] Clin Chem. 2002 Jan;48(1):61-8 [11751539.001]
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):1005-11 [12401802.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):100-6 [12517784.001]
  • [Cites] Mol Pharmacol. 2003 May;63(5):1094-103 [12695538.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Mol Pharmacol. 2003 Aug;64(2):456-65 [12869651.001]
  • (PMID = 16333308.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine
  • [Other-IDs] NLM/ PMC2361089
  •  go-up   go-down


41. Eusni RM, Hamidah Hussin N, Zarina AL, Rahman J: Bone marrow necrosis preceding infantile acute lymphoblastic leukaemia. Malays J Pathol; 2007 Dec;29(2):113-7
MedlinePlus Health Information. consumer health - Bone Marrow Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow necrosis preceding infantile acute lymphoblastic leukaemia.
  • We report a case of bone marrow necrosis preceding infantile acute lymphoblastic leukaemia (ALL).
  • Bone marrow necrosis is a rare antemortem event and has been known to be present in many conditions, notably in haematological malignancies like acute lymphoblastic leukaemia.
  • His subsequent marrow 2 weeks later revealed acute lymphoblastic leukaemia (FAB-L1) and immunophenotyping showed precursor B acute lymphoblastic leukaemia-null type.
  • He was started on United Kingdom Acute Lymphoblastic leukaemia (UK ALL) Infantile Leukaemia protocol, however, he defaulted treatment after 3 days.
  • [MeSH-major] Bone Marrow Diseases / complications. Bone Marrow Diseases / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108404.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


42. Szpecht D, Derwich K, Wachowiak J, Konatkowska B, Dworacki G: [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1041-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
  • We report a case of a 4-year-old girl with diagnosed proB acute lymphoblastic leukaemia with co-expression CD33 antigen, treated according to Acute Lymphoblastic Leukaemia Intercontinental - Berlin Frankfurt Münster 2002 (ALL-IC BFM 2002) protocol for standard risk group.
  • The late isolated bone marrow relapse of acute myeloid leukaemia, type 7 was noted in our patient.
  • We recognized this case as a lineage switch acute lymphoblastic leukaemia to acute myeloid leukaemia.
  • In spite of Ida Flag regimen and following Acute Myeloid Leukaemia - Berlin Frankfurt Münster 2004 (AML-BFM 2004) protocol were administered, the clinical and haematological remission was not achieved and the patient died because of disease progression (circulatory and respiratory insufficiency).
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Cell Lineage. Cell Transformation, Neoplastic. Child, Preschool. Daunorubicin / therapeutic use. Disease Progression. Fatal Outcome. Female. Humans. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531823.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


43. Moghadam A, Talebi-Taher M, Dehghan A: Sacroiliitis as an initial presentation of acute lymphoblastic leukaemia. Acta Clin Belg; 2010 May-Jun;65(3):197-9
MedlinePlus Health Information. consumer health - Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacroiliitis as an initial presentation of acute lymphoblastic leukaemia.
  • The pathologist reported Acute Lymphoblastic Leukaemia.
  • The reported patient is the first case of acute lymphoblastic leukaemia, accompanied by sacroiliitis.
  • [MeSH-major] Arthritis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Sacroiliac Joint

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669789.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


44. Aoki CA, Bowlus CL, Rossaro L: An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction. Dig Liver Dis; 2005 Mar;37(3):206-10
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction.
  • We describe an adult case of acute lymphoblastic leukaemia presenting as an acute hepatitis.
  • Due to the elevation in the patient's transaminases and bilirubin, standard acute lymphoblastic leukaemia induction therapy could not be used.
  • [MeSH-major] Liver Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888287.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone
  •  go-up   go-down


45. Sengul E, Dervisoglu E, Kus E, Ciftci E, Ercin C, Yilmaz A: Acute lymphoblastic leukaemia presenting with acute renal failure: report of two cases. J Pak Med Assoc; 2008 Sep;58(9):512-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia presenting with acute renal failure: report of two cases.
  • Here we report two patients with acute lymphoblastic leukaemia presenting with acute renal failure due to leukaemic infiltration.
  • The first patient died before the administration of specific therapy for leukaemia, whereas the second case recovered after chemotherapy.
  • [MeSH-major] Acute Kidney Injury / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Pak Med Assoc. 2008 Dec;58(12):719
  • (PMID = 18846803.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


46. Cecchinato V, Chiaramonte R, Nizzardo M, Cristofaro B, Basile A, Sherbet GV, Comi P: Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol; 2007 Dec 3;74(11):1568-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells.
  • Resveratrol acts both by suppressing cell proliferation and inducing apoptosis in a variety of cancer cell lines.
  • In this study, we show that RES induces apoptosis in MOLT-4 acute lymphoblastic leukaemia cells by modulating three different pathways that regulate cells survival and cell death.
  • [MeSH-minor] Anticarcinogenic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Glycogen Synthase Kinase 3 / genetics. Glycogen Synthase Kinase 3 / metabolism. Humans. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Lithium Chloride / pharmacology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-akt / metabolism. Receptors, Notch / genetics. Receptors, Notch / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sesquiterpenes. Signal Transduction / drug effects. Terpenes / pharmacology. Time Factors. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / genetics. bcl-2-Associated X Protein / metabolism

  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. LITHIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868649.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Receptors, Notch; 0 / Sesquiterpenes; 0 / Stilbenes; 0 / Terpenes; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 37297-20-4 / phytoalexins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3; G4962QA067 / Lithium Chloride; Q369O8926L / resveratrol
  •  go-up   go-down


47. Gottardo NG, Hoffmann K, Beesley AH, Freitas JR, Firth MJ, Perera KU, de Klerk NH, Baker DL, Kees UR: Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol; 2007 May;137(4):319-28
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia.
  • In the last four decades the survival of patients with newly diagnosed childhood T-cell acute lymphoblastic leukaemia (T-ALL) has improved dramatically.
  • [MeSH-major] Gene Expression Profiling. Leukemia-Lymphoma, Adult T-Cell / genetics. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17456054.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95475
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BTG3 protein, human; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / Genetic Markers; 0 / NOTCH2 protein, human; 0 / Proteins; 0 / Receptor, Notch2
  •  go-up   go-down


48. Cooke NS, Feighery C, Armstrong DK, Walsh M, Dempsey S: Cutaneous Fusarium solani infection in childhood acute lymphoblastic leukaemia. Clin Exp Dermatol; 2009 Jul;34(5):e117-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous Fusarium solani infection in childhood acute lymphoblastic leukaemia.
  • We describe a case of widespread cutaneous involvement after infection with Fusarium solani in childhood acute lymphoblastic leukaemia that responded successfully to treatment with prolonged liposomal amphotericin B.
  • [MeSH-major] Dermatomycoses / complications. Fusarium / isolation & purification. Opportunistic Infections / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438533.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Pazur M, Jelić-Puskarić B, Planinc-Peraica A, Vrhovac R, Kardum-Skelin I, Jaksić B: T lymphoblastic leukaemia with an unusual Burkitt lymphoma morphology--a case report. Coll Antropol; 2010 Jun;34(2):675-8
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T lymphoblastic leukaemia with an unusual Burkitt lymphoma morphology--a case report.
  • Precursor T-cell acute lymphoblastic leukaemia (T-ALL)/lymphoma (T-LBL) is a neoplasm with cytological features that include blast cells of medium size, high nuclear cytoplasmic ratio and inconspicuous nucleoli, which are usually TdT (Terminal Deoxynucleotidyl Transferase) positive and variably express T-cell markers.
  • Bone marrow aspiration revealed 87% and peripheral blood 41% of lymphoblasts with cytoplasmic vacuoles which suggested Burkitt lymphoma (BL) morphology.
  • This excluded Burkitt lymphoma and led to diagnosis of T-ALL.
  • The patient was submitted to two cycles of chemotherapy, autologous stem cell transplantation, and intrathecal chemotherapy, but he died after 10 months because of disease complications (lung aspergillosis and pleural effusion).
  • Beside morphologic criteria, setting correct diagnosis depends on identification of immunophenotype by flow cytometry and cytogenetic-molecular abnormalities.
  • [MeSH-major] Burkitt Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antigens, CD2 / analysis. Bone Marrow / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Fatal Outcome. Humans. Karyotyping. Lymphocytes / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698152.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, CD2
  •  go-up   go-down


50. Arestis NJ, Mackinlay GA, Hendry GM: Intussusception in children with ALL receiving chemotherapy for acute lymphoblastic leukaemia. Pediatr Blood Cancer; 2005 Nov;45(6):838-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intussusception in children with ALL receiving chemotherapy for acute lymphoblastic leukaemia.
  • We describe two cases of intussuception of the bowel in children receiving chemotherapy for acute lymphoblastic leukaemia (ALL) and discuss how a high clinical suspicion is critical for the correct diagnosis to be made rapidly.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Intussusception / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16047363.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


51. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D: Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol; 2009 Feb;10(2):147-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.
  • BACKGROUND: About a fifth of children with acute T-lymphoblastic leukaemia (T-ALL) succumb to the disease, suggesting an unrecognised biological heterogeneity that might contribute to drug resistance.
  • We postulated that T-ALL originating from early T-cell precursors (ETPs), a recently defined subset of thymocytes that retain stem-cell-like features, would respond poorly to lymphoid-cell-directed therapy.
  • FINDINGS: 30 patients (12.6%) had leukaemic lymphoblasts with an ETP-related gene-expression signature or its associated distinctive immunophenotype (CD1a(-), CD8(-), CD5(weak) with stem-cell or myeloid markers).
  • Patients with this form of leukaemia had high risk of remission failure or haematological relapse (72% [95% CI 40-100] at 10 years vs 10% [4-16] at 10 years for patients with typical T-ALL treated at St Jude Children's Research Hospital; and 57% [25-89] at 2 years vs 14% [6-22] at 2 years for patients treated in the AIEOP trial).

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Mar 1;105(5):1930-6 [15522952.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3131-7 [16384926.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4714-20 [16954520.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5742-9 [17179108.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):421-38 [17579063.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):9-21 [18097446.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):764-7 [18401411.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):768-72 [18401412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1696-707 [10557041.001]
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):59-75 [10986407.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] Blood. 2004 Jan 15;103(2):442-50 [14504110.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Nat Immunol. 2004 Mar;5(3):247-53 [14985712.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]
  • [Cites] Blood. 1990 Jan 1;75(1):166-73 [1688495.001]
  • [Cites] Leukemia. 1993 Jan;7(1):35-40 [8418377.001]
  • [Cites] Blood. 1993 Aug 1;82(3):889-94 [7687897.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1684-93 [8826928.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2214-21 [9196133.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Blood. 1998 Jul 15;92(2):596-9 [9657760.001]
  • [CommentIn] Lancet Oncol. 2009 Feb;10(2):105-6 [19185830.001]
  • (PMID = 19147408.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA060419-12; United States / NCI NIH HHS / CA / R01 CA060419-12; United States / NCI NIH HHS / CA / CA060419-10; United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA060419-11; United States / NCI NIH HHS / CA / R01 CA060419-10; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / R01 CA060419-11; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS118479; NLM/ PMC2840241
  •  go-up   go-down


52. Kang MH, Harutyunyan N, Hall CP, Papa RA, Lock RB: Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma. Br J Haematol; 2009 May;145(3):389-93
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma.
  • Due to the development of neurological toxicity and resistance to methotrexate (MTX), other antifolates have been evaluated for its potential replacement in the treatment of childhood acute lymphoblastic leukaemia (ALL).
  • AMT activity, compared with MTX, was evaluated in ALL and lymphoma preclinical models.
  • The minimum survival fraction at the range of concentrations tested was lower with AMT than with MTX in 3 out of 15 cell lines.
  • [MeSH-major] Aminopterin / therapeutic use. Folic Acid Antagonists / therapeutic use. Lymphoma / drug therapy. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Female. Humans. Inhibitory Concentration 50. Mice. Mice, SCID. Recurrence. Regression Analysis. Xenograft Model Antitumor Assays


53. Gökbuget N, Hoelzer D: Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol; 2006;19(4):701-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel antibody-based therapy for acute lymphoblastic leukaemia.
  • In recent decades rapid improvements in the results of treatment of adult acute lymphoblastic leukaemia (ALL) have been achieved.
  • This progress has been based mainly on intensification and optimization of chemotherapy, risk-adapted use of stem-cell transplantation, and improved supportive care.
  • In ALL, rituximab is combined with chemotherapy mainly in mature B-ALL and Burkitt's lymphoma, and interim results are very promising.
  • Recently studies with rituximab have also been initiated in B-precursor ALL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997178.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD
  • [Number-of-references] 54
  •  go-up   go-down


54. Idris M, Farid J, Sarwar J, Ahmed S, Wiqar MA, Badsha S: Response rate of Pakistani children with acute lymphoblastic leukaemia to Medical Research Council acute lymphoblastic leukaemia 97 chemotherapy protocol. J Ayub Med Coll Abbottabad; 2010 Jul-Sep;22(3):8-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response rate of Pakistani children with acute lymphoblastic leukaemia to Medical Research Council acute lymphoblastic leukaemia 97 chemotherapy protocol.
  • BACKGROUND: Acute lymphoblastic leukaemia (ALL), a malignancy of lymphoid lineage cells, has excellent prognosis in children.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Protocols. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22338406.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


55. Nygren MK, Døsen G, Hystad ME, Stubberud H, Funderud S, Rian E: Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. Br J Haematol; 2007 Feb;136(3):400-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines.
  • Acute lymphoblastic leukaemia (ALL) is the most common malignancy in children.
  • This study found that Wnt3A induced beta-catenin accumulation in both primary B-ALL cells and B-ALL leukaemia cell lines.
  • Further, Wnt3A was shown to induce nuclear translocation of beta-catenin and TCF/Lef-1 dependent transcriptions in the B-ALL cell line Nalm-6.
  • Functional analyses showed that Wnt3A inhibited the proliferation of several, but not all, B-ALL cell lines studied.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Signal Transduction / physiology. Wnt Proteins / pharmacology
  • [MeSH-minor] Blotting, Western / methods. Cell Line, Tumor. Cell Proliferation. Gene Expression Profiling. Humans. Microscopy, Confocal. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Transcription Factors / genetics. Transcription Factors / metabolism. Tumor Cells, Cultured. Wnt3 Protein. Wnt3A Protein. beta Catenin / genetics. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156404.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / WNT3A protein, human; 0 / WNT5A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / beta Catenin
  •  go-up   go-down


56. Nasir TA, Kabir A: Chemotherapy induced toxicities in therapeutic trials of Acute Lymphoblastic Leukaemia. Mymensingh Med J; 2005 Jan;14(1):61-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy induced toxicities in therapeutic trials of Acute Lymphoblastic Leukaemia.
  • It is common practice in therapeutic trials in Acute Lymphoblastic Leukaemia (ALL) to treat chemotherapy induced toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695958.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


57. Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, Marguerite G, Mazingue F, Renard M, Lutz P, Rialland X, Mechinaud F, Cavé H, Baila L, Bertrand Y, Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC): Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer; 2008 Apr;44(6):840-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial.
  • From June 1989 through to November 1998, 121 children with newly diagnosed T-cell lymphoblastic lymphoma (T-LBL) were included in the EORTC 58881 trial conducted by the Children's Leukaemia Group.
  • An intensive acute lymphoblastic leukaemia type chemotherapy regimen without irradiation leads to a high cure and survival rate in childhood T-LBL without an increased CNS recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342502.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-18; United States / NCI NIH HHS / CA / 5U10-CA11488-19; United States / NCI NIH HHS / CA / 5U10-CA11488-20; United States / NCI NIH HHS / CA / 5U10-CA11488-21; United States / NCI NIH HHS / CA / 5U10-CA11488-22; United States / NCI NIH HHS / CA / 5U10-CA11488-23; United States / NCI NIH HHS / CA / 5U10-CA11488-24; United States / NCI NIH HHS / CA / 5U10-CA11488-25; United States / NCI NIH HHS / CA / 5U10-CA11488-26; United States / NCI NIH HHS / CA / 5U10-CA11488-27; United States / NCI NIH HHS / CA / 5U10-CA11488-28; United States / NCI NIH HHS / CA / 5U10-CA11488-29; United States / NCI NIH HHS / CA / 5U10-CA11488-30; United States / NCI NIH HHS / CA / 5U10-CA11488-31; United States / NCI NIH HHS / CA / 5U10-CA11488-32; United States / NCI NIH HHS / CA / 5U10-CA11488-33; United States / NCI NIH HHS / CA / 5U10-CA11488-34; United States / NCI NIH HHS / CA / 5U10-CA11488-35; United States / NCI NIH HHS / CA / 5U10-CA11488-36
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Philippet P; Otten J; Plouvier E; Béhar C; Boutard P; Millot F; Waterkeyn C; Velde IV; Solbu G
  •  go-up   go-down


58. Krawczuk-Rybak M, Solarz E, Wojtkowska M, Wysocka J: [Gonadal function in boys prior to treatment for acute lymphoblastic leukaemia]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1008-13
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gonadal function in boys prior to treatment for acute lymphoblastic leukaemia].
  • The aim of this study was to evaluate the gonadal function in boys with newly-diagnosed acute lymphoblastic leukaemia, prior to therapy.
  • PATIENTS AND METHODS: The analysis was evaluated in 48 boys with acute lymphoblastic leukaemia, at the time of diagnosis; 34 boys were prepubertal - Tanner stage of sexual maturation 1 (group I) and 14 - pubertal - Tanner stage 3-5 (group II).
  • CONCLUSION: In adolescent boys with newly diagnosed leukaemia, lowered inhibin B values may suggest the damage of spermatogenesis even before the start of chemo- and radiotherapy.
  • [MeSH-major] Gonadal Disorders / blood. Gonadal Disorders / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531817.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / inhibin B; 3XMK78S47O / Testosterone; 57285-09-3 / Inhibins; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


59. Hasanbegović E: [Acute lymphoblastic leukaemia as a secondary malignoma after treatment of acute myeloic leukaemia (AML/M4)]. Med Arh; 2006;60(5):315-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukaemia as a secondary malignoma after treatment of acute myeloic leukaemia (AML/M4)].
  • We report about very rare case of ten years old boy with diagnose of acute myeloic leukaemia which was diagnosed in his age of five (March of 2000) at Pediatric Clinic in Sarajevo.
  • Just 7 months after transplantation boy had relaps of illness in the form of acute lymphoblastic leukaemia (ALL/L2).
  • Complete therapeutic protocol for acute lymphoblastic leukaemia was done and now boy is in complete clinical and hematologic remission.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944736.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


60. Hitoglou-Hatzi S, Hatzistilianou M, Gougoustamou D, Rekliti A, Agguridaki Ch, Athanassiadou F, Frydas S, Kotsis A, Catriu D: Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia. Clin Exp Med; 2005 Jul;5(2):60-5
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia.
  • Neutropenia as a state of immunosuppression is probably the major problem in patients suffering from acute lymphoblastic leukaemia undergoing intensive chemotherapy.
  • The aim of this work was to study sensitive markers for early diagnosis of microbial infection in neutropenic children undergoing intensive chemotherapy as a treatment for acute lymphoblastic leukaemia.
  • The study included three groups (A, B and C) of children with acute lymphoblastic leukaemia and neutropenia.
  • In conclusion, this study suggests procalcitonin and total ADA activity as two easily measurable and cost effective markers for the assessment of immune response in febrile neutropenic patients with acute lymphoblastic leukaemia.
  • [MeSH-major] Adenosine Deaminase / blood. Calcitonin / blood. Fever / blood. Neutropenia / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Protein Precursors / blood

  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096855.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Protein Precursors; 56645-65-9 / procalcitonin; 9007-12-9 / Calcitonin; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


61. Warner JT: Body composition, exercise and energy expenditure in survivors of acute lymphoblastic leukaemia. Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):456-61; discussion 468
MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition, exercise and energy expenditure in survivors of acute lymphoblastic leukaemia.
  • Survivors of acute lymphoblastic leukaemia (ALL) are recognised to become overweight and this seems to worsen with increasing length of follow up.
  • [MeSH-major] Body Composition. Energy Metabolism. Exercise / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064643.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


62. Pui CH, Jeha S: New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov; 2007 Feb;6(2):149-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapeutic strategies for the treatment of acute lymphoblastic leukaemia.
  • Although contemporary treatments cure more than 80% of children with acute lymphoblastic leukaemia (ALL), some patients require intensive treatment and many patients still develop serious acute and late complications owing to the side effects of the treatments.
  • These include new formulations of existing chemotherapeutic agents, new antimetabolites and nucleoside analogues, monoclonal antibodies against leukaemia-associated antigens, and molecular therapies that target genetic abnormalities of the leukaemic cells and their affected signalling pathways.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268486.001).
  • [ISSN] 1474-1776
  • [Journal-full-title] Nature reviews. Drug discovery
  • [ISO-abbreviation] Nat Rev Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Nucleosides
  • [Number-of-references] 166
  •  go-up   go-down


63. Izraeli S: Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside? Br J Haematol; 2010 Oct;151(2):119-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?
  • The remarkable progress in the treatment of childhood acute lymphoblastic leukaemia (ALL) has been based on the adjustment of therapy to subgroups of leukaemia stratified by their prognostic implications.
  • [MeSH-major] Genomics / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20678159.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


64. Le QH, Thomas X, Ecochard R, Iwaz J, Lhéritier V, Michallet M, Fiere D: Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol; 2006 Dec;77(6):471-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia.
  • Factors able to predict overall survival in adult patients with acute lymphoblastic leukaemia were assessed according to the period since initiation of the treatment using a Cox proportional hazards model.
  • From 1994 to 2002, 922 patients with acute lymphoblastic leukaemia (excluding French-American-British L3 subtype) were enrolled in a multicentre protocol and followed, with a mean follow up of 58 months.
  • Determination of such factors is crucial to adapt postremission therapeutic strategies in acute lymphoblastic leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978239.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Denmark
  •  go-up   go-down


65. Peters C, Schrauder A, Schrappe M, von Stackelberg A, Stary J, Yaniv I, Gadner H, Klingebiel T, BFM Study Group, the IBFM-Study Group and the Paediatric Disease Working Party of the EBMT: Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplant; 2005 Mar;35 Suppl 1:S9-11
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts.
  • Children with high risk or relapsed acute lymphoblastic leukaemia (ALL) can benefit from allogeneic haematopoietic stem cell transplantation (SCT).
  • To reduce transplantation-associated complications, the BFM study group, the IBFM study group and the PD-WP-EBMT initiated a prospective cooperative multicentre trail for paediatric ALL patients with an indication for allogeneic stem cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Practice Guidelines as Topic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812540.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


66. McNeer JL, Nachman JB: The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol; 2010 Jun;149(5):638-52
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers.
  • Glucocorticoids are an integral component of therapy for acute lymphoblastic leukaemia (ALL), but usage differs between cooperative group protocols.
  • [MeSH-major] Glucocorticoids / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20408842.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone; VB0R961HZT / Prednisone
  • [Number-of-references] 56
  •  go-up   go-down


67. Styczynski J, Wysocki M: Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia. Br J Haematol; 2006 May;133(4):397-9
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia.
  • We hypothesised that the intensity of mechanisms of glucocorticoid resistance in childhood acute lymphoblastic leukaemia might be decreased by concurrent ex vivo use of compounds with specific blocking or activating properties at different steps of the glucocorticoid intracellular pathway.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prednisolone / pharmacology
  • [MeSH-minor] Cell Death / drug effects. Child. Drug Resistance, Neoplasm / drug effects. Drug Screening Assays, Antitumor / methods. Drug Synergism. Humans. Recurrence. Signal Transduction / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643446.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


68. Kuchinskaya E, Heyman M, Grandér D, Linderholm M, Söderhäll S, Zaritskey A, Nordgren A, Porwit-Macdonald A, Zueva E, Pawitan Y, Corcoran M, Nordenskjöld M, Blennow E: Children and adults with acute lymphoblastic leukaemia have similar gene expression profiles. Eur J Haematol; 2005 Jun;74(6):466-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children and adults with acute lymphoblastic leukaemia have similar gene expression profiles.
  • OBJECTIVES: To compare the gene expression pattern in children and adults with acute lymphoblastic leukaemia (ALL) in order to improve our understanding of the difference in disease biology and prognosis.
  • RESULTS: Unsupervised hierarchical cluster analysis revealed that, in spite of differences in outcome, patients clustered irrespective of age, first by T-cell or B-precursor immunophenotype, and second by cytogenetic changes within the B-precursor group.
  • No significant difference in gene expression was observed between samples with and without CDKN2A deletion within the B-precursor group.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876250.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


69. Chowdhury S, Mandal C: O-acetylated sialic acids: multifaceted role in childhood acute lymphoblastic leukaemia. Biotechnol J; 2009 Mar;4(3):361-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O-acetylated sialic acids: multifaceted role in childhood acute lymphoblastic leukaemia.
  • Childhood acute lymphoblastic leukaemia (ALL), a malignant transformation of the lymphoblasts, is highly responsive to chemotherapy.
  • Additionally, cell surface overexpression of 9-O-acetylated sialoglycoproteins and antibodies against them present in patients' sera aid the survival of the malignant lymphoblasts and suggest a multifaceted role played by these molecules.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sialic Acids / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19296441.001).
  • [ISSN] 1860-7314
  • [Journal-full-title] Biotechnology journal
  • [ISO-abbreviation] Biotechnol J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Glycolipids; 0 / Glycoproteins; 0 / Sialic Acids
  • [Number-of-references] 57
  •  go-up   go-down


70. Cross SA, Lyseng-Williamson KA: Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs; 2007;67(17):2645-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.
  • * Imatinib inhibits the breakpoint cluster region-Abelson (BCR-ABL) tyrosine kinase, which is produced by the chromosomal abnormality known as the Philadelphia (Ph) chromosome in patients with Ph chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL).
  • * In 22 patients receiving imatinib prior to undergoing allogeneic stem cell tranplantation (SCT) in the phase II trial and expanded-access study, estimated disease-free survival and overall survival rates 12 months after SCT were 25.5% and 44.8%.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Philadelphia Chromosome. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Pyrimidines / administration & dosage

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18034597.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 51
  •  go-up   go-down


71. Lo KC, Chalker J, Strehl S, Neat M, Smith O, Dastugue N, Kearney L, Izraeli S, Kempski H, Cowell JK: Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome. Br J Haematol; 2008 Sep;142(6):934-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome.
  • Twenty-five cases of B-cell precursor acute lymphoblastic leukaemia (ALL) from Down syndrome (DS) patients were analyzed using array comparative genomic hybridization (aCGH) and compared with two other subgroups of non-DS patients with ALL; five cases with high-hyperdiploidy (HH) and nine cases with ETV6-RUNX1 positive clones.
  • Seven cases of DS-acute megakaryoblastic leukaemia (AMKL) were also included, DS-ALL cases showed relatively stable karyotypes with cryptic losses and gains that most frequently involved chromosomes X, 1, 2, 9, 11, 16, and 17.
  • [MeSH-major] Chromosome Aberrations. Down Syndrome / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Jun;146(1):113-5 [19344409.001]
  • (PMID = 18557744.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


72. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, Vora A, Mitchell CD, Harrison CJ: Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol; 2010 May;11(5):429-38
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.
  • BACKGROUND: Chromosomal abnormalities in childhood acute lymphoblastic leukaemia are well established disease markers and indicators of outcomes.
  • METHODS: We analysed cytogenetic data from 1725 children with B-cell precursor acute lymphoblastic leukaemia who were included in the UK Medical Research Council ALL97/99 study and followed up for a median time of 8.2 years.
  • Multivariate analysis incorporating age, white-cell count, and treatment parameters showed that six cytogenetic abnormalities (ETV6-RUNX1, high hyperdiploidy, iAMP21, t(9;22), loss of 13q, and abnormal 17p) retained their significance for effect on relapse risk.
  • FUNDING: Leukaemia and Lymphoma Research (LLR).
  • [MeSH-major] Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet Oncol. 2010 May;11(5):403-4 [20409755.001]
  • [ErratumIn] Lancet Oncol. 2010 Jun;11(6):516
  • (PMID = 20409752.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130; United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


73. Qazi S, Uckun FM: Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets. Br J Haematol; 2010 Jun;149(6):865-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets.
  • This study compared the gene expression profiles of primary leukaemic cells from infants versus children with acute lymphoblastic leukaemia (ALL).
  • Our study demonstrated that primary leukaemia cells from infant ALL patients expressed significantly higher levels of genes for cytokines that mediate their biological effects through stimulation of the JAK-STAT signal transduction pathway including interleukin 1a, interleukin 1b, interleukin 2, and interleukin 7.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377589.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / JAK3 protein, human; 0 / Neoplasm Proteins; EC 2.7.10.2 / Janus Kinase 3; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


74. Jurkowska M, Malinowska I, Bal J: [Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood]. Przegl Lek; 2005;62(12):1412-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood].
  • Current treatment strategies of leukaemia use risk factors existing at the time of diagnosis to establish risk-adapted therapy.
  • This approach currently results in overall 95% rate of complete remission in paediatric acute lymphoblastic leukemia (ALL).
  • This suggests the existence of factors independent from leukaemia genetic background, which influences the outcome of patients with ALL.
  • [MeSH-major] Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786762.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 2.5.1.18 / Glutathione Transferase
  • [Number-of-references] 33
  •  go-up   go-down


75. Tong H, Zhang J, Lu C, Liu Z, Zheng Y: Immunophenotypic, cytogenetic and clinical features of 113 acute lymphoblastic leukaemia patients in China. Ann Acad Med Singapore; 2010 Jan;39(1):49-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic, cytogenetic and clinical features of 113 acute lymphoblastic leukaemia patients in China.
  • INTRODUCTION: The analysis of immunophenotype of the leukaemic cells has been of great importance for the diagnosis, classification and prognosis of acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20126815.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


76. Pieters R: [Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%]. Ned Tijdschr Geneeskd; 2010;154:A1577
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%].
  • Acute lymphoblastic leukaemia (ALL) is the most prevalent type of cancer in patients under the age of 18 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Stem Cell Transplantation. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858304.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


77. Sørensen GV, Helgestad J, Rosthøj S: [Varicella-associated morbidity in children undergoing chemotherapy for acute lymphoblastic leukaemia]. Ugeskr Laeger; 2009 Nov 9;171(46):3354-9
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Varicella-associated morbidity in children undergoing chemotherapy for acute lymphoblastic leukaemia].
  • INTRODUCTION: In children with cancer, varicella can be complicated by visceral dissemination with a risk of fatal outcome, especially in children with acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Chickenpox / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925741.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Chickenpox Vaccine; X4HES1O11F / Acyclovir
  •  go-up   go-down


78. Meisel R, Toschke AM, Heiligensetzer C, Dilloo D, Laws HJ, von Kries R: Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia. Br J Haematol; 2007 Jun;137(5):457-60
MedlinePlus Health Information. consumer health - Pneumococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia.
  • There are no current data available on the risk of IPD in children with acute lymphoblastic leukaemia (ALL), the most common type of childhood malignancy.
  • [MeSH-major] Pneumococcal Infections / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Streptococcus pneumoniae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488489.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


79. Domenech C, Mercier M, Plouvier E, Puraveau M, Bordigoni P, Michel G, Benoit Y, Leverger G, Baruchel A, Bertrand Y: First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study. Eur J Cancer; 2008 Nov;44(16):2461-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study.
  • We report on the efficiency of treatment of first isolated extramedullary relapse of B-cell precursor acute lymphoblastic leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804997.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


80. Schrappe M: Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia. Radiat Prot Dosimetry; 2008;132(2):130-3
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
  • Systematic enrollment of children and adolescents with acute lymphoblastic leukaemia (ALL) into clinical trials has allowed the establishment of prognostic parameters derived from initial diagnostic findings.
  • Some problems that are related to the specificity of the parameters used for risk assessment were not overcome: high tumour load by white blood cell count (WBC), age and (rare) cytogenetic subtypes (e.g. t9;22) may characterise a significant proportion of children and adolescents with high-risk ALL.
  • This may facilitate innovative chemotherapy approaches and a more rational use of allogeneic haematopoetic stem cell transplantation.
  • [MeSH-major] Clinical Trials as Topic. Disease Outbreaks / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Risk Assessment / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017727.001).
  • [ISSN] 0144-8420
  • [Journal-full-title] Radiation protection dosimetry
  • [ISO-abbreviation] Radiat Prot Dosimetry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


81. Nebral K, König M, Harder L, Siebert R, Haas OA, Strehl S: Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia. Br J Haematol; 2007 Oct;139(2):269-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia.
  • PAX5 encodes the B-cell lineage specific activator protein (BSAP) and is required for B-cell development and maintenance.
  • In B-cell precursor acute lymphoblastic leukaemia (ALL), PAX5 is involved in several chromosome translocations that fuse the N-terminal paired DNA-binding domain of PAX5 with the C-terminal regulatory sequences of ETV6, FOXP1, ZNF521 or ELN.
  • Herein, we describe the identification of a novel recurrent t(9;15)(p13;q24) in two cases of childhood ALL, which results in an in-frame fusion of PAX5 to the promyelocytic leukaemia (PML) gene.
  • The steadily increasing number of PAX5 rearrangements suggests that PAX5 is not only crucial for B-cell lymphopoiesis but also for the development of B-cell malignancies.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897302.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human
  •  go-up   go-down


82. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature; 2007 Apr 12;446(7137):758-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.
  • Chromosomal aberrations are a hallmark of acute lymphoblastic leukaemia (ALL) but alone fail to induce leukaemia.
  • These findings suggest that direct disruption of pathways controlling B-cell development and differentiation contributes to B-progenitor ALL pathogenesis.
  • [MeSH-major] Genome, Human / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Alleles. B-Cell-Specific Activator Protein / genetics. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Child. DNA-Binding Proteins / genetics. Gene Amplification / genetics. Genomics. Humans. Molecular Sequence Data. Point Mutation / genetics. Sequence Deletion / genetics. Trans-Activators / genetics. Translocation, Genetic / genetics


83. Heath JA, Ramzy JM, Donath SM: Physical activity in survivors of childhood acute lymphoblastic leukaemia. J Paediatr Child Health; 2010 Apr;46(4):149-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical activity in survivors of childhood acute lymphoblastic leukaemia.
  • AIM: To objectively measure levels of physical activity in children, following treatment for acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Motor Activity. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20105252.001).
  • [ISSN] 1440-1754
  • [Journal-full-title] Journal of paediatrics and child health
  • [ISO-abbreviation] J Paediatr Child Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


84. Swerts K, De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philippé J: Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer; 2006 Feb;42(3):295-309
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia.
  • An important problem in the treatment of children with acute lymphoblastic leukaemia (ALL) is pre-existent or acquired resistance to structurally and functionally unrelated chemotherapeutic compounds.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Multidrug Resistance-Associated Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324833.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1
  • [Number-of-references] 144
  •  go-up   go-down


85. Couto E, Chen B, Hemminki K: Association of childhood acute lymphoblastic leukaemia with cancers in family members. Br J Cancer; 2005 Nov 28;93(11):1307-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of childhood acute lymphoblastic leukaemia with cancers in family members.
  • Children whose twins have had leukaemia have a higher risk of contracting acute lymphoblastic leukaemia (ALL), confirming a prenatal origin of the disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):388-91 [11161404.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):990-3 [11286482.001]
  • [Cites] Lancet. 2001 Sep 1;358(9283):711-7 [11551577.001]
  • [Cites] Acta Oncol. 2001;40(6):772-7 [11765074.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):935-41 [11808713.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):83-7 [15068830.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6429-44 [15322515.001]
  • [Cites] Lancet. 1990 Sep 8;336(8715):577-82 [1975376.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):306-12 [1738180.001]
  • [Cites] Am J Epidemiol. 1992 Oct 15;136(8):916-24 [1456268.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] Med Pediatr Oncol. 1996 Apr;26(4):223-9 [8600332.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1941-53 [10711237.001]
  • (PMID = 16288301.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361521
  •  go-up   go-down


86. Fernández-Teijeiro Alvarez A, Galán del Río P, Quintero Calcaño V, Montiano Jorge JI, Astigarraga Aguirre I, Navajas Gutiérrez A: [Subcutaneous nodules as a sign of malignant lymphoproliferative syndrome]. An Pediatr (Barc); 2009 Aug;71(2):148-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Nódulos subcutáneos como forma de presentación de síndrome linfoproliferativo maligno.
  • Immunophenotype confirmed the diagnosis of Precursor B Cell Lymphoblastic Leukemia-Lymphoma.
  • Although complete remission was achieved at the end of the induction chemotherapy according Euro-LB-02 protocol for stage IV, the patient presented a refractory leukaemia relapse thirteen months after diagnosis.
  • Differential diagnosis of malignant skin lesions in children, especially in infants, must include mainly secondary involvement of leukaemia, lymphoma, metastases of neuroblastoma or rhabdomyosarcoma and less frequently other primary processes.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Skin Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19477699.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


87. Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R: Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol; 2005 Jul;153(1):81-9
MedlinePlus Health Information. consumer health - Obesity in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in young adult survivors of childhood acute lymphoblastic leukaemia.
  • OBJECTIVE: Obesity is frequently reported in patients treated for childhood leukaemia.
  • DESIGN: All patients treated for acute lymphoblastic leukaemia (ALL) before the onset of puberty in the region of western Sweden, between 1973 and 1985, and in first remission, were included.
  • CONCLUSIONS: We found little effect on BMI but an increased percentage of total body fat, especially trunk fat, and a tendency for an unfavourable lipid profile in adult survivors of childhood leukaemia.

  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994749.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin; 0 / Lipids
  •  go-up   go-down


88. Chen HY, Ge Z, Wu YJ, Wu LY, Sun M, Tian T, Qiou HR, Liu P, Li JY: [Immunophenotypic analysis of Philadelphia chromosome positive acute lymphoblastic leukaemia in adults]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun;18(3):714-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotypic analysis of Philadelphia chromosome positive acute lymphoblastic leukaemia in adults].
  • The aim of this study was to explore the immunophenotypic characteristics of Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukaemia (ALL) in adults and to evaluate their significance in predicting prognosis and guiding clinical treatment of diseases.
  • The cell immunophenotypes of leukemic marrow or blood samples from 35 cases of Ph(+) ALL and 59 cases of Philadelphia chromosome negative (Ph(-)) ALL were detected by multiparameter flow cytometry, and their abnormal expressions were analysed.
  • The results showed that the expression of all the Ph(+)ALL cases was found in B-cell lineage.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20561435.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


89. Nyári TA, Kajtár P, Bartyik K, Thurzó L, McNally R, Parker L: Seasonal variation of childhood acute lymphoblastic leukaemia is different between girls and boys. Pathol Oncol Res; 2008 Dec;14(4):423-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seasonal variation of childhood acute lymphoblastic leukaemia is different between girls and boys.
  • The aim of this study was to investigate seasonal trends in the incidence of acute lymphoblastic leukaemia (ALL) around the times of birth and diagnosis in children aged 0-4 years and also to examine gender specific effects.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Seasons

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409021.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


90. Mukherjee K, Chava AK, Mandal C, Dey SN, Kniep B, Chandra S, Mandal C: O-acetylation of GD3 prevents its apoptotic effect and promotes survival of lymphoblasts in childhood acute lymphoblastic leukaemia. J Cell Biochem; 2008 Oct 15;105(3):724-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O-acetylation of GD3 prevents its apoptotic effect and promotes survival of lymphoblasts in childhood acute lymphoblastic leukaemia.
  • We have previously demonstrated induction of O-acetylated sialoglycoproteins on lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).
  • Here, we have observed enhanced levels of 9-O-acetylated GD3 (9-O-AcGD3) in the lymphoblasts of patients and leukaemic cell line versus disialoganglioside GD3 in comparison to the normal cells.
  • In situ de-O-acetylation of 9-O-AcGD3 with sodium salicylate restores the GD3-responsiveness to apoptotic signals.
  • [MeSH-major] Apoptosis. Gangliosides / metabolism. Lymphocytes / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Acetylation. Caspase 3 / metabolism. Cell Cycle. Cell Survival. Cytochromes c / metabolism. Humans. Membrane Potential, Mitochondrial. Microscopy, Confocal. Microscopy, Immunoelectron

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18655184.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gangliosides; 62010-37-1 / ganglioside, GD3; 9007-43-6 / Cytochromes c; 98743-26-1 / 9-O-acetyl-GD3 ganglioside; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


91. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature; 2008 May 1;453(7191):110-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
  • The Philadelphia chromosome, a chromosomal abnormality that encodes BCR-ABL1, is the defining lesion of chronic myelogenous leukaemia (CML) and a subset of acute lymphoblastic leukaemia (ALL).
  • To define oncogenic lesions that cooperate with BCR-ABL1 to induce ALL, we performed a genome-wide analysis of diagnostic leukaemia samples from 304 individuals with ALL, including 43 BCR-ABL1 B-progenitor ALLs and 23 CML cases.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Gene Deletion. Ikaros Transcription Factor / deficiency. Ikaros Transcription Factor / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


92. Norén-Nyström U, Heyman M, Frisk P, Golovleva I, Sundström C, Porwit A, Roos G, Bergh A, Forestier E: Vascular density in childhood acute lymphoblastic leukaemia correlates to biological factors and outcome. Br J Haematol; 2009 Sep;146(5):521-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular density in childhood acute lymphoblastic leukaemia correlates to biological factors and outcome.
  • The issue of angiogenesis and its clinical relevance in childhood acute lymphoblastic leukaemia (ALL) is controversial.
  • In the present study, microvessel density (MVD), analysed in 185 diagnostic bone marrow biopsies, was higher in T-cell ALL compared to B-cell precursor (BCP)-ALL (P = 0.013).
  • In the BCP group, cases with t(12;21) were characterized by a low MVD while patients with high-hyperdiploid leukaemia (HeH, 51-61 chromosomes) showed a high MVD compared to other BCP patients (P = 0.001 and 0.002 respectively).
  • There was a correlation between MVD and white blood cell (WBC) count in high-risk BCP patients (P = 0.021).
  • [MeSH-major] Microvessels / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Bone Marrow Examination. Child. Child, Preschool. Core Binding Factor Alpha 2 Subunit / genetics. Cytogenetic Analysis. Female. Humans. Leukocyte Count. Male. Neovascularization, Pathologic. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prognosis. Proportional Hazards Models. Reticulin / ultrastructure. Reverse Transcriptase Polymerase Chain Reaction / methods. Risk. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594745.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Reticulin; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


93. Tantawy AA, Hassanein SM, Adly AA, Saeed OM, Darwish YW, El Aziz AA: Somatosensory evoked potential for detection of subclinical neuropathy in Egyptian children with acute lymphoblastic leukaemia. Pak J Biol Sci; 2010 Jun 1;13(11):527-36
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatosensory evoked potential for detection of subclinical neuropathy in Egyptian children with acute lymphoblastic leukaemia.
  • To evaluate neurological changes developing during paediatric Acute Lymphoblastic Leukaemia (ALL) therapy clinically and through electrophysiological Study of Somatosensory Evoked Potentials (SSEPs) changes in different phases of therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / blood. Methotrexate / blood. Neurotoxicity Syndromes / complications. Neurotoxicity Syndromes / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21848066.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


94. Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg SM, Wayne AS, Pastan I: Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol; 2010 Aug;150(3):352-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia (ALL) remains the most frequent cause of cancer-related mortality in paediatrics and outcome is poor for patients who have high-risk ALL or relapse.
  • Using a bone marrow mesenchymal cell culture assay to support ALL cell viability, we investigated the in vitro cytotoxicity of HA22 against ALL blasts from newly diagnosed (n = 13) and relapsed patients (n = 22).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bacterial Toxins / pharmacology. Exotoxins / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Sialic Acid Binding Ig-like Lectin 2 / immunology
  • [MeSH-minor] Adolescent. Antineoplastic Agents, Hormonal / pharmacology. Cell Death / drug effects. Child. Child, Preschool. Dexamethasone / pharmacology. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Female. Humans. Infant. Lethal Dose 50. Male. Tumor Cells, Cultured. Young Adult

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528877.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Bacterial Toxins; 0 / Exotoxins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / immunotoxin HA22; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


95. Gmidène A, Sennana H, Elghezal H, Ziraoui S, Youssef YB, Elloumi M, Issaoui L, Harrabi I, Raynaud S, Saad A: Cytogenetic analysis of 298 newly diagnosed cases of acute lymphoblastic leukaemia in Tunisia. Hematol Oncol; 2008 Jun;26(2):91-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis of 298 newly diagnosed cases of acute lymphoblastic leukaemia in Tunisia.
  • Genetic changes associated with Acute Lymphoblastic Leukaemia (ALL) provide diagnostic and prognostic information with a direct impact on patient management.
  • [MeSH-major] Chromosomes / ultrastructure. Cytogenetics / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271061.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH: Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev; 2005 Nov;19(6):289-300
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
  • Acute lymphoblastic leukaemia (ALL) responds well to chemotherapy and the majority of children and a significant proportion of adults are cured of their disease after primary therapy.
  • The infusion of unmodified donor lymphocytes (DLI) following relapse after allogeneic transplantation has been shown to be curative in patients with chronic myeloid leukaemia (CML).
  • Other approaches include exploiting the expression of leukaemia-specific antigens such as the proteinase PR-3 or the zinc finger transcription factor Wilms tumour-1 protein (WT-1) to stimulate CTL responses.
  • [MeSH-major] Immunotherapy, Adoptive. Lymphocyte Transfusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adult. Child. Child, Preschool. Dendritic Cells / immunology. Dendritic Cells / transplantation. Female. Graft vs Leukemia Effect / immunology. Humans. Male. Neoplasm Proteins / immunology. Secondary Prevention. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / transplantation. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / transplantation. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275419.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 89
  •  go-up   go-down


97. Brouwer C, De Abreu RA, Keizer-Garritsen JJ, Lambooy LH, Ament K, ter Riet PG, van Wering ER, Trijbels FJ, Veerman AJ, Hoogerbrugge PM, Bökkerink JP: Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects. Eur J Cancer; 2005 Mar;41(4):613-23
Hazardous Substances Data Bank. TRIMETHOPRIM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects.
  • TPMT activities and genotypes have been determined in patients with acute lymphoblastic leukaemia (ALL) and in control children.
  • Median red blood cell (RBC) TPMT activity in ALL patients at diagnosis was significantly lower than in controls (median 11.5 pmol/10(7) RBC*hr; range 1.7-30.7; n = 191 vs. 14.6 pmol/10(7) RBC*hr; range 1.6-50.7; n = 140).
  • [MeSH-major] Methyltransferases / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737567.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; AN164J8Y0X / Trimethoprim; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


98. Lazić J, Dokmanović L, Krstovski N, Predojević J, Tosić N, Pavlović S, Janić D: [Immunoglobulin genes and T-cell receptors as molecular markers in children with acute lymphoblastic leukaemia]. Srp Arh Celok Lek; 2009 Jul-Aug;137(7-8):384-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunoglobulin genes and T-cell receptors as molecular markers in children with acute lymphoblastic leukaemia].
  • INTRODUCTION: Acute lymphoblastic leukaemia (ALL) is a malignant clonal disease, one of the most common malignancies in childhood.
  • [MeSH-major] Gene Rearrangement. Immunoglobulin Heavy Chains / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764592.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


99. Sadakane Y, Zaitsu M, Nishi M, Sugita K, Mizutani S, Matsuzaki A, Sueoka E, Hamasaki Y, Ishii E: Expression and production of aberrant PAX5 with deletion of exon 8 in B-lineage acute lymphoblastic leukaemia of children. Br J Haematol; 2007 Jan;136(2):297-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and production of aberrant PAX5 with deletion of exon 8 in B-lineage acute lymphoblastic leukaemia of children.
  • Summary We investigated PAX5 expression in childhood B-lineage acute lymphoblastic leukaemia (ALL).
  • By Western blotting, healthy controls displayed Pax5-FL, while one short Pax5, derived from the deletion of exon 8 (Pax5-DeltaE8) was produced in 90% of ALL samples, as well as in ALL cell lines.
  • PAX5-DeltaE8 lacked more than 50% of the transactivation domain, indicating that aberrant Pax5 production might lead to the arrest of B-cell differentiation, contributing to the pathogenesis of B-lineage ALL.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129225.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / B cell linker protein; 0 / B-Cell-Specific Activator Protein; 0 / RNA, Messenger
  •  go-up   go-down


100. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J: Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies. Acta Paediatr; 2006 Jun;95(6):701-6
Genetic Alliance. consumer health - Tetanus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies.
  • AIM: To investigate the possible relationship between serum levels and avidities of antibodies against tetanus toxoid (TT) and Haemophilus influenzae type b (Hib) in children that were vaccinated after treatment for childhood acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Antibodies, Bacterial / immunology. Antibody Affinity. Haemophilus Vaccines / immunology. Haemophilus influenzae / immunology. Polysaccharides, Bacterial / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Tetanus Toxoid / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754551.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Haemophilus Vaccines; 0 / Haemophilus influenzae type b polysaccharide vaccine; 0 / Polysaccharides, Bacterial; 0 / Tetanus Toxoid
  •  go-up   go-down






Advertisement